Cargando…

Neovascularization in Tissue Engineering

A prerequisite for successful tissue engineering is adequate vascularization that would allow tissue engineering constructs to survive and grow. Angiogenic growth factors, alone and in combination, have been used to achieve this, and gene therapy has been used as a tool to enable sustained release o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jennifer C.-Y., Shum-Tim, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901123/
https://www.ncbi.nlm.nih.gov/pubmed/24710553
http://dx.doi.org/10.3390/cells1041246
_version_ 1782300803117088768
author Chung, Jennifer C.-Y.
Shum-Tim, Dominique
author_facet Chung, Jennifer C.-Y.
Shum-Tim, Dominique
author_sort Chung, Jennifer C.-Y.
collection PubMed
description A prerequisite for successful tissue engineering is adequate vascularization that would allow tissue engineering constructs to survive and grow. Angiogenic growth factors, alone and in combination, have been used to achieve this, and gene therapy has been used as a tool to enable sustained release of these angiogenic proteins. Cell-based therapy using endothelial cells and their precursors presents an alternative approach to tackling this challenge. These studies have occurred on a background of advancements in scaffold design and assays for assessing neovascularization. Finally, several studies have already attempted to translate research in neovascularization to clinical use in the blossoming field of therapeutic angiogenesis.
format Online
Article
Text
id pubmed-3901123
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-39011232014-04-07 Neovascularization in Tissue Engineering Chung, Jennifer C.-Y. Shum-Tim, Dominique Cells Review A prerequisite for successful tissue engineering is adequate vascularization that would allow tissue engineering constructs to survive and grow. Angiogenic growth factors, alone and in combination, have been used to achieve this, and gene therapy has been used as a tool to enable sustained release of these angiogenic proteins. Cell-based therapy using endothelial cells and their precursors presents an alternative approach to tackling this challenge. These studies have occurred on a background of advancements in scaffold design and assays for assessing neovascularization. Finally, several studies have already attempted to translate research in neovascularization to clinical use in the blossoming field of therapeutic angiogenesis. MDPI 2012-12-10 /pmc/articles/PMC3901123/ /pubmed/24710553 http://dx.doi.org/10.3390/cells1041246 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Chung, Jennifer C.-Y.
Shum-Tim, Dominique
Neovascularization in Tissue Engineering
title Neovascularization in Tissue Engineering
title_full Neovascularization in Tissue Engineering
title_fullStr Neovascularization in Tissue Engineering
title_full_unstemmed Neovascularization in Tissue Engineering
title_short Neovascularization in Tissue Engineering
title_sort neovascularization in tissue engineering
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901123/
https://www.ncbi.nlm.nih.gov/pubmed/24710553
http://dx.doi.org/10.3390/cells1041246
work_keys_str_mv AT chungjennifercy neovascularizationintissueengineering
AT shumtimdominique neovascularizationintissueengineering